|
|
|
Using sound Clinical Paths and Diagnosis-related
Groups (DRGs)-based payment reform to bring benefits to patient care:
A case study of leukemia therapy |
| Zhi-Ruo ZHANG PhD1,Jian-Qing MI MD1,Zhao-Jun WEN MA1,Sai-Juan CHEN MD, PhD1,Zhu CHEN PhD1,Long-Jun GU MD2,Jing-Yan TANG MD2,PhD, Shu-Hong SHEN MD, PhD2, |
| 1.Shanghai Institute of
Hematology, Rui-Jin Hospital Affiliated with Shanghai Jiao Tong University
School of Medicine, Shanghai 200025, China; 2.Department of Hematology/Oncology,
Shanghai Children’s Medical Center Affiliated with Shanghai
Jiao Tong University School of Medicine, Shanghai 200127, China; |
|
|
|
|
Abstract China has been undertaking a profound reform on health care. Although more than 1.16 billion people have been covered by rural and urban medical insurance to date, the level of reimbursement from insurance is very limited, especially for critical diseases such as leukemia. This places heavy economic burdens on patients. Under these circumstances, systems innovation is imperative for the efficient utilization of limited funding. In this respect, certain valuable experience from other countries may prove helpful. The prospective payment system of Diagnosis-related Groups (DRGs), Clinical Paths, and the Comparative Effectiveness Analysis adopted by the National Institute of Health and Clinical Excellence (NICE, UK), can be fine tools to reduce medical costs and improve quality of services. Treatments of acute promyelocytic leukemia at Rui-Jin Hospital, and childhood acute lymphoblastic leukemia at Shanghai Children’s Medical Center, can be taken as suitable models to illustrate the crucial role of Clinical Paths in guaranteeing clinical and cost effectiveness of medical services for critical diseases, and to satisfactorily justify the feasibility of DRGs in China.
|
| Keywords
healthcare reform
diagnosis-related groups
clinical paths
comparative effectiveness analysis
acute promyelocytic leukemia
childhood acute lymphoblastic leukemia
|
|
Issue Date: 05 March 2010
|
|
|
news.xinhuanet.com/newscenter/2009-04/07/content_11142999_1.htm (in Chinese)
|
|
news.xinhuanet.com/newscenter/2009-04/07/content_11142999_1.htm (in Chinese)
|
|
http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohbgt/s6717/200908/42282.htm
|
|
finance.people.com.cn/GB/9815328.html (in Chinese)
|
|
Chen Z. Launch of the health-care reform plan in China. Lancet, 2009, 373 (9672): 1322–1324
doi: 10.1016/S0140-6736(09)60753-4
|
|
Mayes R. The origins, development, and passage of Medicare’srevolutionary prospective payment system. J Hist Med Allied Sci, 2007, 62(1): 21–55
doi: 10.1093/jhmas/jrj038
|
|
Reid B, Sutch S. Comparing diagnosis-relatedgroup systems to identify design improvement. Health Policy, 2008, 87(1): 82–91
doi: 10.1016/j.healthpol.2007.12.012
|
|
Diagnosis Related Groups (DRGs)and the Medicare program: implications for medical technology—atechnical memorandum. Washington D.C.: US Congress, Office of Technology Assessment, OTA-TM-H-17. 1983
|
|
Levit K R, Freeland S. Nationalmedical care spending. Health Aff, Winter1988, 124–136
doi: 10.1377/hlthaff.7.5.124
|
|
Pearson S D, Goulart-Fisher D, Lee TH. Critical pathways as a strategyfor improving care: problems and potential. Ann Intern Med, 1995, 123 (12): 941–948
|
|
torch.cs.dal.ca/~asharma/OWL/Role%2520of%2520Clinical%2520Pathways.pdf
|
|
Weiland D E. Why use clinical pathways rather than practice guidelines? Am J Surg, 1997, 174(6): 592–595
doi: 10.1016/S0002-9610(97)00196-7
|
|
Rotter T, Kugler J, Koch R, Gothe H, Twork S, van Oostrum J M, Steyerberg E W. A systematic review and meta-analysis of the effectsof clinical pathways on length of stay, hospital costs and patientoutcomes. BMC Health Serv Res, 2008, 8: 265
|
|
Rouse A D, Tripp B L, Shipley S, Pories W, Cunningham P, MacDonald K Jr. Meeting the challenge of managed care through clinicalpathways for bariatric surgery. Obes Surg, 1998, 8(5): 530–534
doi: 10.1381/096089298765554106
|
|
Dowsey M M, Kilgour M L, Santamaria N M, Choong P F. Clinical pathways in hip and knee arthroplasty: a prospectiverandomised controlled study. Med J Aust, 1999, 170(2): 59–62
|
|
Birch S, Gafni A. On being NICEin the UK: guidelines for technology appraisal for the NHS in Englandand Wales. Health Econ, 2002, 11(3): 185–191
doi: 10.1002/hec.706
|
|
Raftery J. NICE: faster access to modern treatments? Analysis ofguidance on health technologies. BMJ, 2001, 323(7324): 1300–1303
doi: 10.1136/bmj.323.7324.1300
|
|
Cheng T M. Medical service quality standards: experiences of theUK’s NICE. Presented at the Conferenceon Health Reform: Global Healthcare Reform Experiences. 2009
|
|
Phillips C. What is a QALY? London: Hayward Medical Communications. 2009
|
|
Wu G H. DRGs’ development and related research in China. Zhongguo Yiyuan Guanli, 2007, 27(7): 10–12 (in Chinese)
|
|
http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3585/200912/44858
|
|
Shen Z X, Shi Z Z, Fang J, Gu B W, Li J M, Zhu Y M, Shi J Y, Zheng P Z, Yan H, Chen Y, Shen Y, Wu W, Tang W, Waxman S, de Thé H, Wang Z Y, Chen S J, Chen Z. All-trans retinoic acid/As2O3 combinationyields a high quality remission and survival in newly diagnosed acutepromyelocytic leukemia. Proc Natl AcadSci USA, 2004, 101(15): 5328–5335.
doi: 10.1073/pnas.0400053101
|
|
Hu J, Liu Y F, Wu CF, Xu F, Shi Z X, Zhu Y M, Li J M, Tang W, Zhao W L, Wu W, Sun H P, Chen Q S, Chen B, Zhou G B, Zelent A, Waxman S, Wang Z Y, Chen S J, Chen Z. Long-termefficacy and safety of all-trans retinoic acid/arsenic trioxide basedtherapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2009, 106(6): 3342–3347
doi: 10.1073/pnas.0813280106
|
|
Liu Y, Chen J, Tang J Y, Ni S X, Xue H L, Pan C. Cost of childhood acute lymphoblastic leukemia care inShanghai, China. Pediatr Blood Cancer, 2009, 53: 557–562
doi: 10.1002/pbc.22127
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
